Cheng L, Li F, Bility MT, Murphy CM, Su L (2015) Modeling hepatitis B virus infection, immunopathology and therapy in mice. Antiviral Res. 6:39520.
Bility MT, Curtis A, Su L (2014) A chimeric mouse model to study immunopathogenesis of HCV infection. Methods Mol Biol. 1213:379-388.
Bility MT, Cheng L, Zhang L, Luan Y, Li F, Chi L, Tu Z, Zhang L, Fu Y, Niu J, Fusheng W, and Su L (2014) Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human specific liver fibrosis and M2-like macrophages. Plos Pathogens. 10:e1004032.
Bility MT and Sripa B (2014) Chronic Opisthorchis viverrini infection and associated hepatobiliary disease is associated with iron loaded – M2 macrophages. Korean Journal of Parasitology. 52:695-699.
Bility MT, Li F, Cheng L and Su L (2013) Liver immune-pathogenesis and therapy of human liver tropic virus infection in humanized mouse models. J Gastroenterol Hepatol. Suppl. 1:120-124.
Bility MT, Zhang L, Washburn ML, Curtis A, Kovalev GI and Su L (2012) Generation of humanized mouse with both immune system and human liver cells: a model for hepatitis C virus infection and immunopathogenesis. Nature Protocols. 7:1608-1617.
Washburn ML, Bility MT, Kovalev GI, Zhang L, Buntzman A, Frelinger JA, Barry W, Ploss A, Rice CM, and Su L (2011) A Humanized Mouse Model to Study Hepatitis C Virus Infection, Immune Response, and Liver Disease. Gastroenterology 140(4):1334-1344.
Borland MG, Krishnan P, Lee C, Albrecht PP, Shan W, Bility MT, Marcus CB, Lin JM, Amin S, Gonzalez FJ, Perdew GH, Peters JM (2014) Modulation of aryl hydrocarbon receptor (AHR)-dependent signaling by peroxisome proliferator-activated receptor β/δ (PPARβ/δ) in keratinocytes. Carcinogenesis. 35:1602-1612.
Zhu B, Ferry CH, Blazanin N, Bility MT, Khozoie C, Kang BH, Glick AB, Gonzalez FJ, Peters JM (2014) PPARβ/δ promotes HRAS-induced senescence and tumor suppression by potentiating p-ERK and repressing p-AKT signaling. Oncogene.33:5348-5359.
Bility MT, Zhu B, Gonzalez FJ, Peters JM (2010) Ligand activation of peroxisome proliferator activated receptor-β/δ (PPARβ/δ) and inhibition of cyclooxygenase 2 (COX2) enhances inhibition of skin tumorigenesis. Toxicological Sciences 113:27-36.
Bility MT, Devlin MK, Blazanin N, Glick AB, Billin AN, Willson TM, Ward JM, Gonzalez FJ, Peters JM (2008) Ligand activation of peroxisome proliferator-activated receptor-b/d (PPARb/d) inhibits skin carcinogenesis. Carcinogenesis 29:2406-2414.
Shan W, Nicol CJ, Ito S, Bility MT, Kennett MJ, Ward JM, Gonzalez FJ, Peters JM (2008) Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice. Hepatology. 47:225-235.
Burdick AD, Bility MT, Girroir EE, Billin AN, Willson TM, Gonzalez FJ, Peters JM (2007) Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) inhibits cell growth of human N/TERT-1 keratinocytes. Cell Signaling 19:1163-1171.
Kim DJ, Bility MT, Billin AN, Willson TM, Gonzalez FJ, Peters JM (2006) PPARbeta/delta selectively induces differentiation and inhibits cell proliferation. Cell Death Differ.13:53-60.
Bility MT, Thompson JT, McKee RH, David RM, Butala JH, Vanden Heuvel JP, Peters JM (2004) Activation of mouse and human peroxisome proliferator- activated receptors (PPARs) by phthalate monoesters. Toxicol Sci 82:170-182.